160 related articles for article (PubMed ID: 32183947)
21. The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia.
Baker A; Gregory GP; Verbrugge I; Kats L; Hilton JJ; Vidacs E; Lee EM; Lock RB; Zuber J; Shortt J; Johnstone RW
Cancer Res; 2016 Mar; 76(5):1158-69. PubMed ID: 26627013
[TBL] [Abstract][Full Text] [Related]
22. Leukemogenic MLL fusion proteins bind across a broad region of the Hox a9 locus, promoting transcription and multiple histone modifications.
Milne TA; Martin ME; Brock HW; Slany RK; Hess JL
Cancer Res; 2005 Dec; 65(24):11367-74. PubMed ID: 16357144
[TBL] [Abstract][Full Text] [Related]
23. Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia.
Brzezinka K; Nevedomskaya E; Lesche R; Steckel M; Eheim AL; Haegebarth A; Stresemann C
J Hematol Oncol; 2019 Jun; 12(1):66. PubMed ID: 31253180
[TBL] [Abstract][Full Text] [Related]
24. Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyond.
Chen CW; Armstrong SA
Exp Hematol; 2015 Aug; 43(8):673-84. PubMed ID: 26118503
[TBL] [Abstract][Full Text] [Related]
25. Expression of HOX genes in acute leukemia cell lines with and without MLL translocations.
Quentmeier H; Dirks WG; Macleod RA; Reinhardt J; Zaborski M; Drexler HG
Leuk Lymphoma; 2004 Mar; 45(3):567-74. PubMed ID: 15160920
[TBL] [Abstract][Full Text] [Related]
26. Genetic deletion or small-molecule inhibition of the arginine methyltransferase PRMT5 exhibit anti-tumoral activity in mouse models of MLL-rearranged AML.
Kaushik S; Liu F; Veazey KJ; Gao G; Das P; Neves LF; Lin K; Zhong Y; Lu Y; Giuliani V; Bedford MT; Nimer SD; Santos MA
Leukemia; 2018 Feb; 32(2):499-509. PubMed ID: 28663579
[TBL] [Abstract][Full Text] [Related]
27. Tumorigenicity of Ewing sarcoma is critically dependent on the trithorax proteins MLL1 and menin.
Svoboda LK; Bailey N; Van Noord RA; Krook MA; Harris A; Cramer C; Jasman B; Patel RM; Thomas D; Borkin D; Cierpicki T; Grembecka J; Lawlor ER
Oncotarget; 2017 Jan; 8(1):458-471. PubMed ID: 27888797
[TBL] [Abstract][Full Text] [Related]
28. The role of menin in hematopoiesis.
Maillard I; Hess JL
Adv Exp Med Biol; 2009; 668():51-7. PubMed ID: 20175452
[TBL] [Abstract][Full Text] [Related]
29. DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia.
Chen CW; Koche RP; Sinha AU; Deshpande AJ; Zhu N; Eng R; Doench JG; Xu H; Chu SH; Qi J; Wang X; Delaney C; Bernt KM; Root DE; Hahn WC; Bradner JE; Armstrong SA
Nat Med; 2015 Apr; 21(4):335-43. PubMed ID: 25822366
[TBL] [Abstract][Full Text] [Related]
30. The miR-17∼92 cluster contributes to MLL leukemia through the repression of MEIS1 competitor PKNOX1.
Mian YA; Zeleznik-Le NJ
Leuk Res; 2016 Jul; 46():51-60. PubMed ID: 27123834
[TBL] [Abstract][Full Text] [Related]
31. ZNF521 sustains the differentiation block in MLL-rearranged acute myeloid leukemia.
Germano G; Morello G; Aveic S; Pinazza M; Minuzzo S; Frasson C; Persano L; Bonvini P; Viola G; Bresolin S; Tregnago C; Paganin M; Pigazzi M; Indraccolo S; Basso G
Oncotarget; 2017 Apr; 8(16):26129-26141. PubMed ID: 28412727
[TBL] [Abstract][Full Text] [Related]
32. Structural insights into inhibition of the bivalent menin-MLL interaction by small molecules in leukemia.
Shi A; Murai MJ; He S; Lund G; Hartley T; Purohit T; Reddy G; Chruszcz M; Grembecka J; Cierpicki T
Blood; 2012 Nov; 120(23):4461-9. PubMed ID: 22936661
[TBL] [Abstract][Full Text] [Related]
33. A MENage à Trois in leukemia.
Roudaia L; Speck NA
Cancer Cell; 2008 Jul; 14(1):3-5. PubMed ID: 18598937
[TBL] [Abstract][Full Text] [Related]
34. A reconfigured pattern of MLL occupancy within mitotic chromatin promotes rapid transcriptional reactivation following mitotic exit.
Blobel GA; Kadauke S; Wang E; Lau AW; Zuber J; Chou MM; Vakoc CR
Mol Cell; 2009 Dec; 36(6):970-83. PubMed ID: 20064463
[TBL] [Abstract][Full Text] [Related]
35. A 2024 Update on Menin Inhibitors. A New Class of Target Agents against KMT2A-Rearranged and NPM1-Mutated Acute Myeloid Leukemia.
Candoni A; Coppola G
Hematol Rep; 2024 Apr; 16(2):244-254. PubMed ID: 38651453
[TBL] [Abstract][Full Text] [Related]
36. Differential regulation of the c-Myc/Lin28 axis discriminates subclasses of rearranged MLL leukemia.
Chen L; Sun Y; Wang J; Jiang H; Muntean AG
Oncotarget; 2016 May; 7(18):25208-23. PubMed ID: 27007052
[TBL] [Abstract][Full Text] [Related]
37. A novel small molecule that kills a subset of MLL-rearranged leukemia cells by inducing mitochondrial dysfunction.
Somers K; Wen VW; Middlemiss SMC; Osborne B; Forgham H; Jung M; Karsa M; Clifton M; Bongers A; Gao J; Mayoh C; Raoufi-Rad N; Kusnadi EP; Hannan KM; Scott DA; Kwek A; Liu B; Flemming C; Chudakova DA; Pandher R; Failes TW; Lim J; Angeli A; Osterman AL; Imamura T; Kees UR; Supuran CT; Pearson RB; Hannan RD; Davis TP; McCarroll J; Kavallaris M; Turner N; Gudkov AV; Haber M; Norris MD; Henderson MJ
Oncogene; 2019 May; 38(20):3824-3842. PubMed ID: 30670779
[TBL] [Abstract][Full Text] [Related]
38. Establishment of an inducible expression system of chimeric MLL-LTG9 protein and inhibition of Hox a7, Hox b7 and Hox c9 expression by MLL-LTG9 in 32Dcl3 cells.
Joh T; Hosokawa Y; Suzuki R; Takahashi T; Seto M
Oncogene; 1999 Jan; 18(4):1125-30. PubMed ID: 10023690
[TBL] [Abstract][Full Text] [Related]
39. Potent antileukemic activity of curaxin CBL0137 against MLL-rearranged leukemia.
Somers K; Kosciolek A; Bongers A; El-Ayoubi A; Karsa M; Mayoh C; Wadham C; Middlemiss S; Neznanov N; Kees UR; Lock RB; Gudkov A; Sutton R; Gurova K; Haber M; Norris MD; Henderson MJ
Int J Cancer; 2020 Apr; 146(7):1902-1916. PubMed ID: 31325323
[TBL] [Abstract][Full Text] [Related]
40. MLL: a histone methyltransferase disrupted in leukemia.
Hess JL
Trends Mol Med; 2004 Oct; 10(10):500-7. PubMed ID: 15464450
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
